3-IMidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-1H-pyrrole-2,5-dione
- $650 - $760
- Product name: 3-IMidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-1H-pyrrole-2,5-dione
- CAS: 603281-60-3
- MF: C28H26N6O3
- MW: 494.54
- EINECS:
- MDL Number:MFCD26142631
- Synonyms:3-IMidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-1H-pyrrole-2,5-dione;HHSIUHRARDLCPM-UHFFFAOYSA-N;1H-Pyrrole-2,5-dione, 3-imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-
2 prices
Selected condition:
Brand
- Medical Isotopes, Inc.
- TRC
Package
- 5mg
- 50mg
- ManufacturerMedical Isotopes, Inc.
- Product number59137
- Product description3-Imidazo[1,2-α]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-1H-pyrrole-2,5-dione
- Packaging5mg
- Price$650
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberI387510
- Product description3-Imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-1H-pyrrole-2,5-dione
- Packaging50mg
- Price$760
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Medical Isotopes, Inc. | 59137 | 3-Imidazo[1,2-α]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-1H-pyrrole-2,5-dione | 5mg | $650 | 2021-12-16 | Buy |
TRC | I387510 | 3-Imidazo[1,2-a]pyridin-3-yl-4-[1,2,3,4-tetrahydro-2-(1-piperidinylcarbonyl)pyrrolo[3,2,1-jk][1,4]benzodiazepin-7-yl]-1H-pyrrole-2,5-dione | 50mg | $760 | 2021-12-16 | Buy |
Properties
Density :1.50±0.1 g/cm3(Predicted)
pka :7.58±0.60(Predicted)
pka :7.58±0.60(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|